Amgen's New Drug MariTide: 20% Weight Loss in 52 Weeks Shocks the Market
Amgen announced that its weight loss therapy, MariTide, achieved positive results in a Phase II clinical study over 52 weeks, showing an average weight loss of about 20% in non-diabetic obese or overweight individuals, without a weight plateau. However, due to high side effects and not surpassing Eli Lilly’s Zepbound, Amgen's stock fell over 12.3%. In the trial, MariTide was taken monthly or less frequently, with a maximum weight loss of 20%. While the effects were comparable to Wegovy and Zepbound, MariTide's oral formulation might be more appealing. Nonetheless, MariTide had significant side effects, with about 11% of patients dropping out due to adverse effects compared to 7% for Zepbound. Amgen stated that nausea and vomiting were typically mild and brief, primarily related to initial dosing, and could be alleviated by adjusting the timing of administration.
2026-10-26
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
INEOS Closes US Polystrene Plant: 400K Tons of PD in the US Can't Hold On
-
Lotte Merges with HD Hyundai: Can Korea’s Petrochemical First Case Trigger True Restructuring?
-
Evonik Cuts 3,200 Jobs: Europe’s Chemical Winter Is Not Over
-
As Middle East Supply Faces Disruptions, SABIC's 1.8 Million Mt/Year Methanol New Project Secures Saudi Feedstock Quota
-
South Korea Moves Urgently to Control Petrochemical Feedstock Hoarding as Supply Chain Risk Escalates to the National Security Level
-
Dow Swings from an $801 Million Loss to an $802 Million Profit as Hormuz Disruption Lifts Polyethylene Prices
-
Türkiye Advances $3 Billion Petrochemical Cluster Targeting 17% of Domestic Polypropylene Demand
-
Argentina to Build Latin America’s Largest Urea Plant Under €1.3 Billion Contract
-
Hormuz Crisis Pushes Up Urea Prices as Yara’s Quarterly EBITDA Jumps 39%
-
AstraZeneca Pays Up to $1.5 Billion for Global Rights to Chinese Lung Cancer Drug
Recommend Reading
-
Nouryon's Production Facilities in China Have Obtained Halal Certification for Personal Care Ingredients
-
Aster Opens Singapore’s Storage and Marine Network to Third Parties
-
Profit Crushed, Layoffs and Restructuring Follow: What WACKER Chemie’s 2025 Performance Reveals
-
Two Major Dye Giants Hike Prices Consecutively: Longsheng Raises Prices by Up to RMB 10,000/Ton, Yabang Increases Some Products by RMB 60,000/Ton
-
$15 Billion Invested in China: AstraZeneca Builds an “Innovation Hub” While Some Are Still Waiting for the Windfall
-
Multiple Positive Factors Support Butadiene Prices Rising Over 29% in January
-
After Reaching a High, Polyester Chip Prices in May Showed Wide Fluctuations at High Levels in China
-
This Week's Styrene Market Continues to Rise (1.26-1.30)
-
Low Levels Across the Entire Cycle + Widening Negative Deviation—Melamine Short-Term Market Weakens
-
China’s New Food-Contact Standards Take Effect, Resetting Compliance for Coatings and Silicone Rubber